Skip to main content

Cardiac Pacemakers

An overview of market access challenges for cardiac pacemaker implantation in European countries.

dcv

Procedure coding

Procedure coding is well-established for cardiac pacemakers in European countries. Implantation, replacement, and removal of cardiac pacemakers are typically coded separately. 

In many countries, the procedure codes for cardiac pacemaker implantation differ depending on its type (single-chamber, dual-chamber, leadless).

For example, in England, there are specific OPCS codes for transvenous implantation (code K60.5 – for single chamber cardiac pacemaker system, code K60.6 – for dual chamber cardiac pacemaker system), renewal (code K73.1 – for single chamber cardiac pacemaker system, code K73.2 – for dual chamber cardiac pacemaker system) and removal of intravenous cardiac pacemaker system (code K60.4). The procedures related to the epicardial pacemaker system are coded separately.

sdfv

Payment mechanism

The payment model for cardiac pacemaker implantation or replacement is DRG in most European countries.

In some countries, the DRG allocation depends on the type of pacemaker (e.g., Austria, England, or Switzerland). In other countries, the clinical indication impacts the DRG allocation (e.g., Denmark, France). For example, in Germany, implantation of a single-chamber cardiac pacemaker is reimbursed via DRG F17B “Replacement of cardiac pacemaker, single-chamber system” with a tariff of €18,087. In contrast, implantation of a dual-chamber pacemaker is allocated to the DRG F17A “Replacement of cardiac pacemaker, multi-chamber system” with a higher tariff of €21,946.

In most European countries, cardiac pacemakers do not attract additional (top-up) reimbursement, which is paid in addition to the DRG tariff. One exception is England, where the intracardiac pacemaker system and wireless pacemakers are included in the High Cost Devices List and reimbursed in addition to the HRG tariff.

cvbgf

Policy considerations

As cardiac pacemaker implantation and replacement procedures are well-established technologies, they are unlikely to be subject to specific policies from payers or national decision-makers in the countries where such frameworks exist.

efdvfb

Health technology assessment

Due to established reimbursement in European countries, cardiac pacemakers rarely become a subject of HTA. 

wedfbgn

Future challenges 

Implementing cardiac pacemakers has established reimbursement and funding in most European countries. New health technology assessments are unlikely to be relevant. It is unlikely to benefit from the innovative payment schemes. 

Novel cardiac pacemakers with unique designs or alternative stimulation modes might need to develop specific procedure codes and adjust payment mechanisms to fully leverage their unique technology or cost profile. 

MTRC has experience with more than seven projects related to cardiac pacemakers in Europe.

News and insights

Recommendations about add-on reimbursement for medical devices in France in February 2025

The French National Authority for Health (HAS) has released new recommendations about add-on reimbursement of medical devices and medical aids from the February 2025 meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Sixteen favorable opinions were published concerning the registration or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). They relate to cardiovascular and peripheral vascular, neurovascular, endocrinology, interventional radiology, nephrology and urology, orthopedic devices, and medical aids.

Recommendations about add-on reimbursement for medical devices in France in January 2025

The French National Authority for Health (HAS) has released new recommendations about add-on reimbursement of medical devices and medical aids from the January 2025 meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Seventeen favorable opinions were published concerning the registration or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). They relate to cardiovascular, endocrine, e-health, interventional radiology, neurology and neurosurgery, orthopedic devices, and medical aids.

Remote monitoring of patients with chronic heart failure will be reimbursed in Belgium

In December 2024, the National Institute for Health and Disability Insurance (INAMI/RIZIV) launched a new agreement (Convention) allowing reimbursement for remote monitoring of patients with chronic heart failure. It will come into force on January 1, 2025. New codes (pseudonomenclature) with fees for packages of care will be used for reimbursement. The packages include monitoring of clinical parameters by patients at home (e.g., blood pressure measurement or pulmonary artery pressure measured by an implanted sensor) and transmission of data via a health app to the remote monitoring team at the hospital.

Get in touch

Contact us to discuss your needs and learn about our services